Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California. GBP drops as BOE vote split seems dovishThe BOE has left rates unchanged in December but a more dovish vote split has weighed on the pound.
13:15, 19 December 2024
A hawkish Fed cut sparks fresh volatilityDiscover how the Federal Reserve's hawkish stance, revised SEP, and delayed inflation targets triggered market volatility, with stocks tumbling, bond yields surging, and a stronger US Dollar reshaping investor outlooks.
12:46, 19 December 2024
Gold Latest: XAU/USD stuck within range ahead of the FOMC meetingGold traders await the FOMC meeting to determine how many rate cuts to expect in 2025.
11:25, 18 December 2024
GBP/USD in focus ahead of FED and BOE meetings Both the Federal Reserve and Bank of England will deliver their updated monetary policies this week, with GBP/USD likely to experience increased momentum.
17:33, 17 December 2024